nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—malignant glioma	0.483	1	CbGaD
Irbesartan—CYP1A2—Carmustine—malignant glioma	0.114	0.569	CbGbCtD
Irbesartan—CYP3A4—Temozolomide—malignant glioma	0.0862	0.43	CbGbCtD
Irbesartan—JUN—endothelium—malignant glioma	0.00396	0.0975	CbGeAlD
Irbesartan—JUN—blood vessel—malignant glioma	0.00365	0.0899	CbGeAlD
Irbesartan—AGTR1—endothelium—malignant glioma	0.00298	0.0734	CbGeAlD
Irbesartan—AGTR1—blood vessel—malignant glioma	0.00275	0.0677	CbGeAlD
Irbesartan—JUN—embryo—malignant glioma	0.00218	0.0536	CbGeAlD
Irbesartan—Transient ischaemic attack—Temozolomide—malignant glioma	0.00214	0.0266	CcSEcCtD
Irbesartan—Lymphopenia—Temozolomide—malignant glioma	0.00211	0.0262	CcSEcCtD
Irbesartan—JUN—brainstem—malignant glioma	0.002	0.0491	CbGeAlD
Irbesartan—JUN—retina—malignant glioma	0.00193	0.0474	CbGeAlD
Irbesartan—Myasthenia—Carmustine—malignant glioma	0.00178	0.0221	CcSEcCtD
Irbesartan—JUN—telencephalon—malignant glioma	0.00177	0.0436	CbGeAlD
Irbesartan—EDNRA—medulla oblongata—malignant glioma	0.00153	0.0376	CbGeAlD
Irbesartan—EDNRA—midbrain—malignant glioma	0.00139	0.0343	CbGeAlD
Irbesartan—JUN—medulla oblongata—malignant glioma	0.00139	0.0343	CbGeAlD
Irbesartan—PTGS1—endothelium—malignant glioma	0.00131	0.0323	CbGeAlD
Irbesartan—JUN—midbrain—malignant glioma	0.00127	0.0313	CbGeAlD
Irbesartan—JUN—spinal cord—malignant glioma	0.00124	0.0306	CbGeAlD
Irbesartan—PTGS1—blood vessel—malignant glioma	0.00121	0.0298	CbGeAlD
Irbesartan—Drug interaction—Carmustine—malignant glioma	0.00121	0.015	CcSEcCtD
Irbesartan—Coordination abnormal—Carmustine—malignant glioma	0.00114	0.0142	CcSEcCtD
Irbesartan—Coordination abnormal—Temozolomide—malignant glioma	0.0011	0.0137	CcSEcCtD
Irbesartan—Musculoskeletal pain—Temozolomide—malignant glioma	0.00109	0.0136	CcSEcCtD
Irbesartan—AGTR1—medulla oblongata—malignant glioma	0.00105	0.0258	CbGeAlD
Irbesartan—Aplastic anaemia—Temozolomide—malignant glioma	0.00102	0.0126	CcSEcCtD
Irbesartan—JUN—central nervous system—malignant glioma	0.00101	0.0248	CbGeAlD
Irbesartan—JUN—cerebellum—malignant glioma	0.000984	0.0242	CbGeAlD
Irbesartan—Diabetes mellitus—Carmustine—malignant glioma	0.000934	0.0116	CcSEcCtD
Irbesartan—Swelling—Carmustine—malignant glioma	0.000921	0.0114	CcSEcCtD
Irbesartan—Ear pain—Temozolomide—malignant glioma	0.00092	0.0114	CcSEcCtD
Irbesartan—Gastroenteritis—Temozolomide—malignant glioma	0.000885	0.011	CcSEcCtD
Irbesartan—Injury—Carmustine—malignant glioma	0.000884	0.011	CcSEcCtD
Irbesartan—EDNRA—brain—malignant glioma	0.000876	0.0216	CbGeAlD
Irbesartan—Hot flush—Temozolomide—malignant glioma	0.000839	0.0104	CcSEcCtD
Irbesartan—Menopausal symptoms—Temozolomide—malignant glioma	0.000832	0.0103	CcSEcCtD
Irbesartan—Hyponatraemia—Carmustine—malignant glioma	0.000815	0.0101	CcSEcCtD
Irbesartan—JUN—brain—malignant glioma	0.000799	0.0197	CbGeAlD
Irbesartan—Face oedema—Carmustine—malignant glioma	0.000784	0.00974	CcSEcCtD
Irbesartan—Affect lability—Temozolomide—malignant glioma	0.000772	0.00959	CcSEcCtD
Irbesartan—AGTR1—central nervous system—malignant glioma	0.000758	0.0187	CbGeAlD
Irbesartan—Face oedema—Temozolomide—malignant glioma	0.000758	0.00941	CcSEcCtD
Irbesartan—Liver function test abnormal—Carmustine—malignant glioma	0.00075	0.00931	CcSEcCtD
Irbesartan—Mood swings—Temozolomide—malignant glioma	0.000743	0.00923	CcSEcCtD
Irbesartan—Hypokalaemia—Carmustine—malignant glioma	0.000739	0.00918	CcSEcCtD
Irbesartan—Muscular weakness—Carmustine—malignant glioma	0.000716	0.0089	CcSEcCtD
Irbesartan—Hypokalaemia—Temozolomide—malignant glioma	0.000714	0.00887	CcSEcCtD
Irbesartan—Breast disorder—Temozolomide—malignant glioma	0.000709	0.00881	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000707	0.00878	CcSEcCtD
Irbesartan—Dysphagia—Carmustine—malignant glioma	0.000702	0.00872	CcSEcCtD
Irbesartan—Muscular weakness—Temozolomide—malignant glioma	0.000692	0.0086	CcSEcCtD
Irbesartan—Abdominal distension—Temozolomide—malignant glioma	0.000683	0.00848	CcSEcCtD
Irbesartan—Dysphagia—Temozolomide—malignant glioma	0.000678	0.00842	CcSEcCtD
Irbesartan—Neutropenia—Carmustine—malignant glioma	0.000656	0.00815	CcSEcCtD
Irbesartan—Neutropenia—Temozolomide—malignant glioma	0.000634	0.00788	CcSEcCtD
Irbesartan—Hyperglycaemia—Carmustine—malignant glioma	0.000633	0.00786	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00063	0.00783	CcSEcCtD
Irbesartan—Pneumonia—Carmustine—malignant glioma	0.000629	0.00782	CcSEcCtD
Irbesartan—Photosensitivity reaction—Temozolomide—malignant glioma	0.000619	0.00769	CcSEcCtD
Irbesartan—Weight increased—Temozolomide—malignant glioma	0.000617	0.00767	CcSEcCtD
Irbesartan—Renal failure—Carmustine—malignant glioma	0.000615	0.00764	CcSEcCtD
Irbesartan—Hyperglycaemia—Temozolomide—malignant glioma	0.000612	0.0076	CcSEcCtD
Irbesartan—Urinary tract infection—Carmustine—malignant glioma	0.000608	0.00756	CcSEcCtD
Irbesartan—Pneumonia—Temozolomide—malignant glioma	0.000608	0.00756	CcSEcCtD
Irbesartan—AGTR1—brain—malignant glioma	0.000602	0.0148	CbGeAlD
Irbesartan—Urinary tract infection—Temozolomide—malignant glioma	0.000588	0.0073	CcSEcCtD
Irbesartan—PTGS1—telencephalon—malignant glioma	0.000586	0.0144	CbGeAlD
Irbesartan—Hepatobiliary disease—Temozolomide—malignant glioma	0.000572	0.0071	CcSEcCtD
Irbesartan—Hypoaesthesia—Carmustine—malignant glioma	0.000559	0.00694	CcSEcCtD
Irbesartan—Oedema peripheral—Carmustine—malignant glioma	0.000553	0.00687	CcSEcCtD
Irbesartan—Connective tissue disorder—Carmustine—malignant glioma	0.000552	0.00686	CcSEcCtD
Irbesartan—CYP2D6—brainstem—malignant glioma	0.000543	0.0134	CbGeAlD
Irbesartan—Hepatitis—Temozolomide—malignant glioma	0.000543	0.00674	CcSEcCtD
Irbesartan—Visual impairment—Carmustine—malignant glioma	0.000541	0.00672	CcSEcCtD
Irbesartan—Hypoaesthesia—Temozolomide—malignant glioma	0.00054	0.00671	CcSEcCtD
Irbesartan—Pharyngitis—Temozolomide—malignant glioma	0.000539	0.00669	CcSEcCtD
Irbesartan—Urinary tract disorder—Temozolomide—malignant glioma	0.000536	0.00666	CcSEcCtD
Irbesartan—Oedema peripheral—Temozolomide—malignant glioma	0.000535	0.00664	CcSEcCtD
Irbesartan—Connective tissue disorder—Temozolomide—malignant glioma	0.000534	0.00663	CcSEcCtD
Irbesartan—Urethral disorder—Temozolomide—malignant glioma	0.000532	0.00661	CcSEcCtD
Irbesartan—Visual impairment—Temozolomide—malignant glioma	0.000523	0.0065	CcSEcCtD
Irbesartan—Flushing—Carmustine—malignant glioma	0.000521	0.00648	CcSEcCtD
Irbesartan—Tinnitus—Temozolomide—malignant glioma	0.000506	0.00629	CcSEcCtD
Irbesartan—Cardiac disorder—Temozolomide—malignant glioma	0.000504	0.00626	CcSEcCtD
Irbesartan—Flushing—Temozolomide—malignant glioma	0.000504	0.00626	CcSEcCtD
Irbesartan—Arrhythmia—Carmustine—malignant glioma	0.000502	0.00623	CcSEcCtD
Irbesartan—Angiopathy—Temozolomide—malignant glioma	0.000493	0.00612	CcSEcCtD
Irbesartan—Immune system disorder—Temozolomide—malignant glioma	0.00049	0.00609	CcSEcCtD
Irbesartan—Mediastinal disorder—Temozolomide—malignant glioma	0.000489	0.00608	CcSEcCtD
Irbesartan—Malnutrition—Carmustine—malignant glioma	0.000489	0.00607	CcSEcCtD
Irbesartan—Erythema—Carmustine—malignant glioma	0.000489	0.00607	CcSEcCtD
Irbesartan—Chills—Temozolomide—malignant glioma	0.000487	0.00605	CcSEcCtD
Irbesartan—CYP2D6—telencephalon—malignant glioma	0.000482	0.0119	CbGeAlD
Irbesartan—Malnutrition—Temozolomide—malignant glioma	0.000473	0.00587	CcSEcCtD
Irbesartan—Erythema—Temozolomide—malignant glioma	0.000473	0.00587	CcSEcCtD
Irbesartan—Dysgeusia—Temozolomide—malignant glioma	0.000463	0.00575	CcSEcCtD
Irbesartan—Vision blurred—Carmustine—malignant glioma	0.000461	0.00572	CcSEcCtD
Irbesartan—Tremor—Carmustine—malignant glioma	0.000458	0.00569	CcSEcCtD
Irbesartan—Anaemia—Carmustine—malignant glioma	0.000452	0.00561	CcSEcCtD
Irbesartan—Agitation—Carmustine—malignant glioma	0.000449	0.00558	CcSEcCtD
Irbesartan—Vision blurred—Temozolomide—malignant glioma	0.000445	0.00553	CcSEcCtD
Irbesartan—Tremor—Temozolomide—malignant glioma	0.000443	0.0055	CcSEcCtD
Irbesartan—Ill-defined disorder—Temozolomide—malignant glioma	0.000439	0.00545	CcSEcCtD
Irbesartan—Leukopenia—Carmustine—malignant glioma	0.000438	0.00544	CcSEcCtD
Irbesartan—Anaemia—Temozolomide—malignant glioma	0.000437	0.00543	CcSEcCtD
Irbesartan—Agitation—Temozolomide—malignant glioma	0.000434	0.00539	CcSEcCtD
Irbesartan—Angioedema—Temozolomide—malignant glioma	0.000432	0.00536	CcSEcCtD
Irbesartan—Malaise—Temozolomide—malignant glioma	0.000426	0.00529	CcSEcCtD
Irbesartan—Vertigo—Temozolomide—malignant glioma	0.000425	0.00527	CcSEcCtD
Irbesartan—Leukopenia—Temozolomide—malignant glioma	0.000423	0.00525	CcSEcCtD
Irbesartan—Hypertension—Carmustine—malignant glioma	0.000422	0.00524	CcSEcCtD
Irbesartan—Chest pain—Carmustine—malignant glioma	0.000416	0.00517	CcSEcCtD
Irbesartan—Myalgia—Carmustine—malignant glioma	0.000416	0.00517	CcSEcCtD
Irbesartan—Anxiety—Carmustine—malignant glioma	0.000415	0.00515	CcSEcCtD
Irbesartan—Cough—Temozolomide—malignant glioma	0.000412	0.00512	CcSEcCtD
Irbesartan—PTGS1—spinal cord—malignant glioma	0.000411	0.0101	CbGeAlD
Irbesartan—Hypertension—Temozolomide—malignant glioma	0.000408	0.00507	CcSEcCtD
Irbesartan—Arthralgia—Temozolomide—malignant glioma	0.000402	0.005	CcSEcCtD
Irbesartan—Myalgia—Temozolomide—malignant glioma	0.000402	0.005	CcSEcCtD
Irbesartan—Anxiety—Temozolomide—malignant glioma	0.000401	0.00498	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.0004	0.00496	CcSEcCtD
Irbesartan—Oedema—Carmustine—malignant glioma	0.000399	0.00496	CcSEcCtD
Irbesartan—Discomfort—Temozolomide—malignant glioma	0.000398	0.00494	CcSEcCtD
Irbesartan—Infection—Carmustine—malignant glioma	0.000397	0.00493	CcSEcCtD
Irbesartan—Dry mouth—Temozolomide—malignant glioma	0.000394	0.00489	CcSEcCtD
Irbesartan—Thrombocytopenia—Carmustine—malignant glioma	0.000391	0.00485	CcSEcCtD
Irbesartan—Tachycardia—Carmustine—malignant glioma	0.00039	0.00484	CcSEcCtD
Irbesartan—Anaphylactic shock—Temozolomide—malignant glioma	0.000386	0.00479	CcSEcCtD
Irbesartan—Oedema—Temozolomide—malignant glioma	0.000386	0.00479	CcSEcCtD
Irbesartan—Infection—Temozolomide—malignant glioma	0.000383	0.00476	CcSEcCtD
Irbesartan—Anorexia—Carmustine—malignant glioma	0.00038	0.00473	CcSEcCtD
Irbesartan—Nervous system disorder—Temozolomide—malignant glioma	0.000378	0.0047	CcSEcCtD
Irbesartan—Thrombocytopenia—Temozolomide—malignant glioma	0.000378	0.00469	CcSEcCtD
Irbesartan—Skin disorder—Temozolomide—malignant glioma	0.000375	0.00465	CcSEcCtD
Irbesartan—Hypotension—Carmustine—malignant glioma	0.000373	0.00463	CcSEcCtD
Irbesartan—Hyperhidrosis—Temozolomide—malignant glioma	0.000373	0.00463	CcSEcCtD
Irbesartan—Anorexia—Temozolomide—malignant glioma	0.000368	0.00457	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000364	0.00452	CcSEcCtD
Irbesartan—Paraesthesia—Carmustine—malignant glioma	0.000358	0.00445	CcSEcCtD
Irbesartan—Dyspnoea—Carmustine—malignant glioma	0.000356	0.00442	CcSEcCtD
Irbesartan—Somnolence—Carmustine—malignant glioma	0.000355	0.00441	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000351	0.00436	CcSEcCtD
Irbesartan—Decreased appetite—Carmustine—malignant glioma	0.000347	0.00431	CcSEcCtD
Irbesartan—Paraesthesia—Temozolomide—malignant glioma	0.000346	0.0043	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Carmustine—malignant glioma	0.000345	0.00428	CcSEcCtD
Irbesartan—Dyspnoea—Temozolomide—malignant glioma	0.000344	0.00427	CcSEcCtD
Irbesartan—Somnolence—Temozolomide—malignant glioma	0.000343	0.00426	CcSEcCtD
Irbesartan—Pain—Carmustine—malignant glioma	0.000341	0.00424	CcSEcCtD
Irbesartan—Constipation—Carmustine—malignant glioma	0.000341	0.00424	CcSEcCtD
Irbesartan—Dyspepsia—Temozolomide—malignant glioma	0.00034	0.00422	CcSEcCtD
Irbesartan—Decreased appetite—Temozolomide—malignant glioma	0.000335	0.00416	CcSEcCtD
Irbesartan—PTGS1—central nervous system—malignant glioma	0.000333	0.00821	CbGeAlD
Irbesartan—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000333	0.00414	CcSEcCtD
Irbesartan—Fatigue—Temozolomide—malignant glioma	0.000333	0.00413	CcSEcCtD
Irbesartan—Constipation—Temozolomide—malignant glioma	0.00033	0.0041	CcSEcCtD
Irbesartan—Pain—Temozolomide—malignant glioma	0.00033	0.0041	CcSEcCtD
Irbesartan—Feeling abnormal—Carmustine—malignant glioma	0.000329	0.00409	CcSEcCtD
Irbesartan—Gastrointestinal pain—Carmustine—malignant glioma	0.000326	0.00405	CcSEcCtD
Irbesartan—CYP2C8—brain—malignant glioma	0.000326	0.00803	CbGeAlD
Irbesartan—Feeling abnormal—Temozolomide—malignant glioma	0.000318	0.00395	CcSEcCtD
Irbesartan—Body temperature increased—Carmustine—malignant glioma	0.000316	0.00392	CcSEcCtD
Irbesartan—Abdominal pain—Carmustine—malignant glioma	0.000316	0.00392	CcSEcCtD
Irbesartan—Gastrointestinal pain—Temozolomide—malignant glioma	0.000315	0.00392	CcSEcCtD
Irbesartan—Urticaria—Temozolomide—malignant glioma	0.000306	0.00381	CcSEcCtD
Irbesartan—Body temperature increased—Temozolomide—malignant glioma	0.000305	0.00379	CcSEcCtD
Irbesartan—Abdominal pain—Temozolomide—malignant glioma	0.000305	0.00379	CcSEcCtD
Irbesartan—Hypersensitivity—Carmustine—malignant glioma	0.000294	0.00365	CcSEcCtD
Irbesartan—Asthenia—Carmustine—malignant glioma	0.000286	0.00356	CcSEcCtD
Irbesartan—Hypersensitivity—Temozolomide—malignant glioma	0.000284	0.00353	CcSEcCtD
Irbesartan—CYP3A4—central nervous system—malignant glioma	0.000278	0.00685	CbGeAlD
Irbesartan—Asthenia—Temozolomide—malignant glioma	0.000277	0.00344	CcSEcCtD
Irbesartan—CYP2D6—central nervous system—malignant glioma	0.000274	0.00674	CbGeAlD
Irbesartan—Diarrhoea—Carmustine—malignant glioma	0.000273	0.00339	CcSEcCtD
Irbesartan—Pruritus—Temozolomide—malignant glioma	0.000273	0.00339	CcSEcCtD
Irbesartan—CYP2D6—cerebellum—malignant glioma	0.000268	0.00659	CbGeAlD
Irbesartan—PTGS1—brain—malignant glioma	0.000265	0.00651	CbGeAlD
Irbesartan—Dizziness—Carmustine—malignant glioma	0.000264	0.00328	CcSEcCtD
Irbesartan—Diarrhoea—Temozolomide—malignant glioma	0.000264	0.00328	CcSEcCtD
Irbesartan—Dizziness—Temozolomide—malignant glioma	0.000255	0.00317	CcSEcCtD
Irbesartan—Vomiting—Carmustine—malignant glioma	0.000254	0.00315	CcSEcCtD
Irbesartan—Rash—Carmustine—malignant glioma	0.000252	0.00313	CcSEcCtD
Irbesartan—Dermatitis—Carmustine—malignant glioma	0.000251	0.00312	CcSEcCtD
Irbesartan—Headache—Carmustine—malignant glioma	0.00025	0.00311	CcSEcCtD
Irbesartan—Vomiting—Temozolomide—malignant glioma	0.000245	0.00305	CcSEcCtD
Irbesartan—Rash—Temozolomide—malignant glioma	0.000243	0.00302	CcSEcCtD
Irbesartan—Dermatitis—Temozolomide—malignant glioma	0.000243	0.00302	CcSEcCtD
Irbesartan—Headache—Temozolomide—malignant glioma	0.000242	0.003	CcSEcCtD
Irbesartan—Nausea—Carmustine—malignant glioma	0.000237	0.00294	CcSEcCtD
Irbesartan—Nausea—Temozolomide—malignant glioma	0.000229	0.00285	CcSEcCtD
Irbesartan—CYP2D6—brain—malignant glioma	0.000217	0.00535	CbGeAlD
Irbesartan—Candesartan—PTGS1—malignant glioma	0.000183	1	CrCbGaD
Irbesartan—EDNRA—Signaling Pathways—RAF1—malignant glioma	1.51e-05	7.73e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CG—malignant glioma	1.51e-05	7.73e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APC—malignant glioma	1.51e-05	7.73e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2B6—malignant glioma	1.5e-05	7.71e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.5e-05	7.67e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.49e-05	7.66e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—malignant glioma	1.49e-05	7.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2B6—malignant glioma	1.49e-05	7.64e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGF—malignant glioma	1.49e-05	7.64e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTPN11—malignant glioma	1.48e-05	7.59e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CB—malignant glioma	1.47e-05	7.54e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CD—malignant glioma	1.47e-05	7.52e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—FGF2—malignant glioma	1.47e-05	7.51e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PDGFRA—malignant glioma	1.45e-05	7.44e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—malignant glioma	1.42e-05	7.26e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—malignant glioma	1.41e-05	7.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SPP1—malignant glioma	1.41e-05	7.23e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.4e-05	7.16e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—malignant glioma	1.4e-05	7.16e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2—malignant glioma	1.39e-05	7.14e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—malignant glioma	1.38e-05	7.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ASMT—malignant glioma	1.38e-05	7.07e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT2—malignant glioma	1.38e-05	7.07e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—malignant glioma	1.38e-05	7.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—IDH1—malignant glioma	1.37e-05	7.05e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—malignant glioma	1.37e-05	7.04e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MDM2—malignant glioma	1.37e-05	7.03e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—RAF1—malignant glioma	1.37e-05	7.01e-05	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—malignant glioma	1.37e-05	7e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.36e-05	6.99e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—IDH1—malignant glioma	1.36e-05	6.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—IDH2—malignant glioma	1.35e-05	6.94e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—malignant glioma	1.35e-05	6.94e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—malignant glioma	1.35e-05	6.93e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—malignant glioma	1.35e-05	6.93e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CAT—malignant glioma	1.34e-05	6.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—malignant glioma	1.34e-05	6.85e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CB—malignant glioma	1.33e-05	6.84e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SPHK1—malignant glioma	1.33e-05	6.82e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CD—malignant glioma	1.32e-05	6.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SPHK1—malignant glioma	1.32e-05	6.76e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.32e-05	6.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—malignant glioma	1.31e-05	6.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PDGFB—malignant glioma	1.3e-05	6.69e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2C18—malignant glioma	1.3e-05	6.68e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGFR1—malignant glioma	1.3e-05	6.65e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—malignant glioma	1.3e-05	6.65e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BCAN—malignant glioma	1.3e-05	6.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2C18—malignant glioma	1.29e-05	6.62e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTT1—malignant glioma	1.28e-05	6.58e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—malignant glioma	1.28e-05	6.56e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CB—malignant glioma	1.28e-05	6.56e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HIF1A—malignant glioma	1.28e-05	6.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.28e-05	6.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2B6—malignant glioma	1.27e-05	6.53e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—malignant glioma	1.27e-05	6.52e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGF2—malignant glioma	1.27e-05	6.5e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—malignant glioma	1.27e-05	6.5e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NCOR1—malignant glioma	1.27e-05	6.49e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—malignant glioma	1.24e-05	6.36e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CAV1—malignant glioma	1.24e-05	6.34e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—malignant glioma	1.23e-05	6.31e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—malignant glioma	1.23e-05	6.28e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—malignant glioma	1.22e-05	6.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.22e-05	6.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS1—malignant glioma	1.2e-05	6.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.2e-05	6.14e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—malignant glioma	1.19e-05	6.11e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MDM2—malignant glioma	1.19e-05	6.08e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RAF1—malignant glioma	1.18e-05	6.06e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—F2—malignant glioma	1.18e-05	6.03e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FN1—malignant glioma	1.18e-05	6.03e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—malignant glioma	1.17e-05	6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—IDH1—malignant glioma	1.16e-05	5.97e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BAD—malignant glioma	1.16e-05	5.96e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CB—malignant glioma	1.15e-05	5.92e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—malignant glioma	1.15e-05	5.91e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH1—malignant glioma	1.15e-05	5.9e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—malignant glioma	1.15e-05	5.89e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—malignant glioma	1.14e-05	5.85e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—malignant glioma	1.14e-05	5.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CD80—malignant glioma	1.13e-05	5.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SPHK1—malignant glioma	1.13e-05	5.78e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—malignant glioma	1.13e-05	5.77e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—malignant glioma	1.13e-05	5.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—BCHE—malignant glioma	1.12e-05	5.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGF—malignant glioma	1.11e-05	5.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—malignant glioma	1.11e-05	5.69e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.11e-05	5.69e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTPN11—malignant glioma	1.11e-05	5.67e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—malignant glioma	1.1e-05	5.66e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—malignant glioma	1.1e-05	5.66e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2C18—malignant glioma	1.1e-05	5.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—malignant glioma	1.07e-05	5.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.07e-05	5.49e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—malignant glioma	1.06e-05	5.45e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—malignant glioma	1.06e-05	5.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—malignant glioma	1.06e-05	5.43e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—malignant glioma	1.06e-05	5.42e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—malignant glioma	1.05e-05	5.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH2—malignant glioma	1.05e-05	5.36e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—malignant glioma	1.04e-05	5.36e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.04e-05	5.36e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.04e-05	5.34e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.04e-05	5.31e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—malignant glioma	1.03e-05	5.3e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CAV1—malignant glioma	1.03e-05	5.29e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—malignant glioma	1.03e-05	5.29e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT2—malignant glioma	1.03e-05	5.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—malignant glioma	1e-05	5.15e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—malignant glioma	9.98e-06	5.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—malignant glioma	9.9e-06	5.07e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS1—malignant glioma	9.88e-06	5.06e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	9.86e-06	5.05e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2B6—malignant glioma	9.83e-06	5.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS1—malignant glioma	9.79e-06	5.02e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—malignant glioma	9.76e-06	5.01e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	9.75e-06	5e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—malignant glioma	9.74e-06	4.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	9.48e-06	4.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGF2—malignant glioma	9.48e-06	4.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—malignant glioma	9.4e-06	4.82e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—malignant glioma	9.37e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—BCHE—malignant glioma	9.18e-06	4.71e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	9.15e-06	4.69e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—BCHE—malignant glioma	9.1e-06	4.67e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—malignant glioma	9.07e-06	4.65e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—malignant glioma	9.07e-06	4.65e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.03e-06	4.63e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—malignant glioma	9.01e-06	4.62e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—malignant glioma	8.99e-06	4.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH1—malignant glioma	8.99e-06	4.61e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—malignant glioma	8.97e-06	4.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—malignant glioma	8.93e-06	4.58e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—malignant glioma	8.92e-06	4.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—malignant glioma	8.9e-06	4.56e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—malignant glioma	8.87e-06	4.55e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—malignant glioma	8.85e-06	4.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAF1—malignant glioma	8.84e-06	4.53e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—malignant glioma	8.74e-06	4.48e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SPHK1—malignant glioma	8.7e-06	4.46e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—malignant glioma	8.68e-06	4.45e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAT—malignant glioma	8.66e-06	4.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—malignant glioma	8.63e-06	4.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2C18—malignant glioma	8.52e-06	4.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.5e-06	4.36e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.42e-06	4.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS1—malignant glioma	8.37e-06	4.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	8.34e-06	4.27e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—malignant glioma	8.29e-06	4.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—malignant glioma	8.29e-06	4.25e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—malignant glioma	8.26e-06	4.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NCOR1—malignant glioma	8.18e-06	4.19e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—malignant glioma	8.13e-06	4.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—malignant glioma	8.11e-06	4.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—malignant glioma	7.94e-06	4.07e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—malignant glioma	7.92e-06	4.06e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—malignant glioma	7.8e-06	4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—BCHE—malignant glioma	7.78e-06	3.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—malignant glioma	7.68e-06	3.94e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—malignant glioma	7.66e-06	3.93e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—malignant glioma	7.5e-06	3.84e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—malignant glioma	7.46e-06	3.82e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.35e-06	3.77e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—malignant glioma	7.33e-06	3.76e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—malignant glioma	7.31e-06	3.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.27e-06	3.72e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—malignant glioma	7.24e-06	3.71e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—malignant glioma	7.2e-06	3.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.2e-06	3.69e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—malignant glioma	7.14e-06	3.66e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAT—malignant glioma	7.11e-06	3.64e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAT—malignant glioma	7.05e-06	3.61e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—malignant glioma	7.04e-06	3.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—malignant glioma	6.89e-06	3.53e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—malignant glioma	6.81e-06	3.49e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—malignant glioma	6.73e-06	3.45e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NCOR1—malignant glioma	6.71e-06	3.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—malignant glioma	6.67e-06	3.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAV1—malignant glioma	6.67e-06	3.42e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NCOR1—malignant glioma	6.65e-06	3.41e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—malignant glioma	6.65e-06	3.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS1—malignant glioma	6.46e-06	3.31e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.37e-06	3.26e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—malignant glioma	6.37e-06	3.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.28e-06	3.22e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—malignant glioma	6.22e-06	3.19e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—malignant glioma	6.2e-06	3.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—malignant glioma	6.19e-06	3.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—malignant glioma	6.07e-06	3.11e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—malignant glioma	6.06e-06	3.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAT—malignant glioma	6.02e-06	3.09e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BCHE—malignant glioma	6e-06	3.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—malignant glioma	5.93e-06	3.04e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—malignant glioma	5.86e-06	3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—malignant glioma	5.75e-06	2.95e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—malignant glioma	5.72e-06	2.93e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOR1—malignant glioma	5.69e-06	2.92e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAV1—malignant glioma	5.47e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAV1—malignant glioma	5.43e-06	2.78e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—malignant glioma	5.34e-06	2.74e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—malignant glioma	5.26e-06	2.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.18e-06	2.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—malignant glioma	5.09e-06	2.61e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—malignant glioma	4.98e-06	2.56e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—malignant glioma	4.94e-06	2.53e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—malignant glioma	4.81e-06	2.47e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—malignant glioma	4.78e-06	2.45e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—malignant glioma	4.77e-06	2.45e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—malignant glioma	4.65e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAT—malignant glioma	4.65e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAV1—malignant glioma	4.64e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—malignant glioma	4.61e-06	2.36e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.43e-06	2.27e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—malignant glioma	4.39e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOR1—malignant glioma	4.39e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—malignant glioma	4.38e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—malignant glioma	4.34e-06	2.23e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—malignant glioma	4.3e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—malignant glioma	4.22e-06	2.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—malignant glioma	4.08e-06	2.09e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—malignant glioma	4.02e-06	2.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.82e-06	1.96e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.79e-06	1.94e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—malignant glioma	3.78e-06	1.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—malignant glioma	3.75e-06	1.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—malignant glioma	3.71e-06	1.9e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—malignant glioma	3.59e-06	1.84e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAV1—malignant glioma	3.58e-06	1.83e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—malignant glioma	3.3e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—malignant glioma	3.27e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.26e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—malignant glioma	3.24e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—malignant glioma	3.21e-06	1.64e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—malignant glioma	3.15e-06	1.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.86e-06	1.47e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—malignant glioma	2.84e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—malignant glioma	2.8e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.5e-06	1.28e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—malignant glioma	2.47e-06	1.27e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.33e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—malignant glioma	2.32e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.31e-06	1.18e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—malignant glioma	2.16e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.97e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—malignant glioma	1.9e-06	9.75e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—malignant glioma	1.89e-06	9.67e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—malignant glioma	1.61e-06	8.26e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.52e-06	7.8e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—malignant glioma	1.24e-06	6.38e-06	CbGpPWpGaD
